orphan diseases

by in

Entry	Author	Date	Location
Has The Pendulum Swung Too Far in Favor of Rare Diseases?	Stewart Lyman	03/14/13	Seattle
Biogen ALS Failure Highlights Clinical Trial Frustrations	Catherine Arnst	01/10/13	Boston
Shire Buys Third Rock’s Lotus Tissue Repair	Catherine Arnst	01/08/13	Boston
Synageva BioPharma Announces $80 Million Stock Offering	Catherine Arnst	01/03/13	Boston
Pfizer, Cystic Fibrosis Foundation in $58 Million Pact	Catherine Arnst	11/19/12	New York
Biotech Racking Up Successes Against Ultra-Orphan Diseases	Catherine Arnst	10/15/12	New York
Xconomist of the Week: Evan Snyder—Stem Cell Reality Check	Bruce V. Bigelow	05/25/12	San Diego
Roche Embraces Three-Way Rare-Disease Play With PTC and Patient Group	Arlene Weintraub	11/30/11	New York
NPS Re-Jiggers Glaxo Partnership, Finds Value in Ultra-Orphan Diseases	Arlene Weintraub	08/09/11	New York
Page 1 of 1

Xconomy National